Thursday, November 5, 2026
ExploreSearch
Via News
MarketCommodities

Corn Futures Went Down By Over 5% In The Last 5 Sessions

Corn Futures Went Down By Over 5% In The Last 5 Sessions

(VIANEWS) - Corn (ZC) has been up by 5.34% for the last 5 sessions. At 05:57 EST on Thursday, 6 April, Corn (ZC) is $625.25.

Volume

Today's last reported volume for Corn is 7045, 93.63% below its average volume of 110748.8.

Volatility

Corn's last week, last month's, and last quarter's current intraday variation average was a negative 1.48%, a negative 0.39%, and a positive 0.88%, respectively.

Corn's highest amplitude of average volatility was 2.74% (last week), 1.06% (last month), and 0.88% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Corn's commodity is considered to be overbought (>=80).

More news about Corn (ZC).

Categories

MarketCommodities

Tags

CommodityCommoditiesFuturesPrice DownCommodities Price DownCommodities NowZCCorn
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
Corn Futures Went Down By Over 5% In The Last 5 Sessions | Via News